Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model

被引:31
|
作者
Kuramoto, Emi
Nishiuma, Teruaki
Kobayashi, Kazuyuki
Yamamoto, Masatsugu
Kono, Yuko
Funada, Yasuhiro
Kotani, Yoshikazu
Sisson, Thomas H. [2 ]
Simon, Richard H. [2 ]
Nishimura, Yoshihiro [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA
关键词
urokinase; plasmin; bronchial asthma; subepithelial fibrosis; HEPATOCYTE GROWTH-FACTOR; INDUCED PULMONARY-FIBROSIS; INDUCED LUNG FIBROSIS; TGF-BETA; INFLAMMATION; INHIBITOR-1; EXPRESSION; COLLAGEN; MICE; ACCUMULATION;
D O I
10.1152/ajplung.90434.2008
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono Y, Funada Y, Kotani Y, Sisson TH, Simon RH, Nishimura Y. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol 296: L337-L346, 2009. First published December 19, 2008; doi: 10.1152/ajplung.90434.2008.-The airway remodeling that occurs in asthma is characterized by an excess of extracellular matrix deposition in the submucosa, hyperplasia/hypertrophy of smooth muscle, goblet cell metaplasia, and accumulation of fibroblasts/myofibroblasts. he urokinase-type plasminogen activator (uPA)/plasmin system participates in pericellular proteolysis and is capable of directly degrading matrix components, activating latent proteinases, and activating growth factors. In a mouse ovalbumin (OVA) asthma model, we increased plasminogen activator activity in the lung by administering exogenous uPA or by using mice genetically deficient in the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) to assess the role of this system in asthma pathogenesis. After intraperitoneal OVA sensitization, mice inhaled OVA plus uPA (500 IU/mouse) or saline by ultrasonic nebulization for 3 wk. When studied 24 h after the final exposure, the groups with upregulated plasmin activity had significantly reduced subepithelial fibrosis within the airway walls and had decreased airway hyperresponsiveness (AHR) to methacholine. Morphometric analysis showed that subepithelial wall thickening of the bronchi (subepithelial area ratio) was also reduced, as were collagen and alpha-smooth muscle actin. Upregulation of plasmin activity also increased the level of hepatocyte growth factor activity in bronchoalveolar lavage fluid, whereas the release of transforming growth factor-beta was decreased. The administration of uPA 1 wk after the last OVA inhalation also significantly reduced lung hydroxyproline content and AHR. These results show that enhancing uPA/plasmin activity lessens the airway remodeling in a murine asthma model.
引用
收藏
页码:L337 / L346
页数:10
相关论文
共 50 条
  • [31] Small molecule inhibitors of urokinase-type plasminogen activator
    Rockway, TW
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (06) : 773 - 786
  • [32] Structure, function and antagonists of urokinase-type plasminogen activator
    Carriero, Maria Vincenza
    Franco, Paola
    Vocca, Imma
    Alfano, Daniela
    Votta, Giuseppina
    Longanesi-Cattani, Immacolata
    Bifulco, Katia
    Mancini, Alessandro
    Caputi, Mario
    Stoppelli, Maria Patrizia
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 3782 - 3794
  • [33] Urokinase-type plasminogen activator receptor in IgA nephropathy
    Ahn, Shin-Young
    Chin, Ho Jun
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2014, 29 (02): : 166 - 169
  • [34] Identification of a novel inhibitor of urokinase-type plasminogen activator
    Zhu, Ming
    Gokhale, Vijay M.
    Szabo, Lajos
    Munoz, Ruben M.
    Baek, Hyounggee
    Bashyam, Sridevi
    Hurley, Laurence H.
    Von Hoff, Daniel D.
    Han, Haiyong
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) : 1348 - 1356
  • [35] Properties of the urokinase-type plasminogen activator modified with phenylglyoxal
    Moukhametova, LI
    Aisina, RB
    Lomakina, GY
    Varfolomeev, SD
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2002, 28 (04) : 278 - 283
  • [36] THE CHICKEN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE
    LESLIE, ND
    KESSLER, CA
    BELL, SM
    DEGEN, JL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1990, 265 (03) : 1339 - 1344
  • [37] Elucidating novel urokinase-type plasminogen activator inhibitors
    Smith, E.
    Spencer, J.
    Ali, M.
    Abdinejad, M.
    Kankanala, J.
    Fishwick, C.
    Philippou, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : E18 - E18
  • [38] A CELLULAR RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    BELIN, D
    BACCINO, D
    WOHLWEND, A
    ESTREICHER, A
    HUARTE, J
    VASSALLI, JD
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 46 - 46
  • [39] Elucidating novel urokinase-type plasminogen activator inhibitors
    Smith, E. L.
    John, S.
    Abdinejad, M.
    Kankanala, J.
    Fishwick, C. W. G.
    Philippou, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 819 - 819
  • [40] Urokinase-type plasminogen activator in carcinomatous pleural fluid
    Ishikawa, H
    Satoh, H
    Hasegawa, S
    Yazawa, T
    Naito, T
    Yamashita, YT
    Ohtsuka, M
    Ogata, T
    Kamma, H
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) : 1566 - 1571